OncoSec Medical Presents Positive Phase 2 Interim Data Evaluating ImmunoPulse in Melanoma

OncoSec Medical Inc. , a company developing its ImmunoPulse DNA-based intratumoral cancer immunotherapy, announced interim data from its Phase 2 melanoma study at the American Society of Clinical Oncology’s 50th Annual Meeting in Chicago.



from Content Keyword RSS http://ift.tt/1rCmd7s

via IFTTT